Skip to main content
Figure 5 | Breast Cancer Research

Figure 5

From: Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation

Figure 5

HER2 downregulation and tumor inhibition by trastuzumab in mouse xenograft tumor models. Tumors from different treatment groups (n = 3) were collected one day after last administration of the antibody. (A) Formaldehyde-fixed BT474 tumor tissues were used for IHC detection of HER2. (B) The same amounts of tumor lysates were loaded on SDS-PAGE and HER2 was detected by WB. (C) Tumor inhibition after four weekly treatments with trastuzumab (tras) or the variant scIgG-T. The left bar graph is from the BT474 tumor model and the right graph is from the MCF7/HER2 tumor model. Percentage of tumor inhibition was calculated, **P <0.01. HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; scIgG-T, single hinge cleaved trastuzumab; WB, Western blotting.

Back to article page